Shankar Thangamani, Ph.D., D.V.M., Ph.D.

Assistant Professor
Glendale, AZ

Home / Academics / Our Faculty / Shankar Thangamani, Ph.D., D.V.M., Ph.D.

Title
Assistant Professor

Campus
Glendale, AZ

College
College of Veterinary Medicine

Department
College of Veterinary Medicine

Program
Veterinary Medicine

Call My
Office

623-537-6360

Send Me
a Message

sthang@midwestern.edu

Education

Purdue University | 2016 | Ph.D.
Madras Veterinary College
India | 2009 | D.V.M.

Courses Taught

VMEDG 1510   Understanding Veterinary Literature

VMEDG 1328   Veterinary Clinical Microbiology

Research

Invasive fungal infections caused by Candida and Cryptococcus are among the most common blood stream and life-threating infections in the immunocompramised individuals particularly among cancer patients, individuals undergoing organ transplantation and HIV infected patients. However, a limited number of approved antifungal drugs in addition to the emergence of fungal strains resistant to current antifungal agents suggest an alternative, novel methods to prevent and treat fungal infections are in urgent need.

(i) Our laboratory is interested in understanding the role of gut metabolites and microbiota in the gastrointestinal (GI) colonization of Candida albicans. Since the majority of C. albicans infections stem from endogenous GI colonization, understanding the mechanism(s) associated with GI colonization is essential to develop novel treatment approachesUtilizing metabolomics, sequencing, in vitro and in vivo mouse models, and clinical samples from humans and animals, understanding the role of gut microbiota and metabolites in the GI colonization of C. albicans will guide personalized medicine and improve drug discovery and development. 

(ii) Our laboratory in collaboration with medicinal chemists, we are involved in developing novel small molecule inhibitors for the treatment of fungal  infections caused by Candida and Cryptococcus species. Our current and future efforts focus on synthesizing and screening novel compounds for antifungal activity, investigating antifungal mechanism of action of lead compounds, and testing the in vivo antifungal efficacy of lead compounds using mice models of fungal infections.

Publications

Antibiotic-induced decreases in the levels of microbial-derived short-chain fatty acids correlate with increased gastrointestinal colonization of Candida albicans. Guinan J, Wang S, Hazbun TR, Yadav H, Thangamani S. Scientific Reports, 2019

Discovery of diazahexa/hepta cyclic cage-like systems compounds with broad-spectrum antifungal activity against Candida and Cryptococcus species. Weinstock A, Arumugam N, Almansour AI, Suresh Kumar R, Thangamani S. RSC Advances. 2019

Broad-spectrum antifungal activity of spirooxindolo-pyrrolidine tethered indole/imidazole hybrid heterocycles against fungal pathogens. Bolous M, Arumugam N, Almansour AI, Suresh Kumar R, Maruoka K, Antharam VC, Thangamani S. Bioorg Med Chem Lett. 2019

Antibiotic-induced alterations in taurocholic acid levels promote gastrointestinal colonization of Candida albicans. Guinan J and Thangamani S. FEMS Microbiology Letters, 2018.

Secondary bile acids inhibit Candida albicans growth and morphogenesis.Guinan J, Villa P and Thangamani S. Pathogens and Disease, 2018.

Benzimidazole tethered pyrrolo[3,4-b]quinoline with broad-spectrum activity against fungal pathogens. Villa P, Arumugam N, Almansour AI, Suresh Kumar R, Mahalingam SM, Maruoka K, Thangamani S. Bioorg Med Chem Lett. 2018

Full Publication List: https://www.ncbi.nlm.nih.gov/pubmed/?term=shankar+thangamani